Clinical ink announces Kaitality™, a first-in-class digital tool for improving drug adherence and measuring functional quality of weight loss
A first-in-class digital tool for improving drug adherence and measuring functional quality of weight loss
Press Release
Clinical ink Appoints Dr. Christian Born Djurhuus, MD, PhD as Chief Science Officer
Dr. Djurhuus commented, “I am excited to join Clinical ink at a time when the convergence of digital health, clinical science, and patient‑centric data capture is creating new opportunities. I look forward to helping advance a disease management solution that delivers meaningful impact for patients while strengthening evidence generation for biopharma partners.”
Clinical ink Appoints Dr. Christian Born Djurhuus, MD, PhD as Chief Science Officer Read More...
Clinical ink Announces SPUR™ Adherence Solution for Cardiometabolic Disease Management in the US
Adherence to treatment plans is essential to optimize clinical outcomes for patients with chronic conditions. SPUR is a unique adherence solution that provides an individual behavioral diagnosis and intervention plan for each patient.
Clinical ink announces collaboration with Tandem Diabetes Care to integrate Automated Insulin Delivery data into the GlucoseReady™ connected device software platform
Integration addresses critical need for accurate, real-time automated insulin delivery data in Type 1 Diabetes clinical research
Clinical ink announces selection as finalist for 2025 Prix Galien USA, “Best Digital Health Solution”
GlucoseReady™ selected as finalist for “Best Digital Health Solution”.
Clinical ink Launches Global Patient Advisory Board to Ensure Engagement in Clinical Technologies
Members from multiple therapeutic areas will incorporate the patient voice into clinical trial technology design.
Clinical ink Launches TrialLens™: An AI-Powered Operations Dashboard for eCOA and Connected Device Trials
AI tool provides real time eCOA and connected device operational data insights.
Clinical ink announces exclusive clinical trial license for the SPUR™ AI-enabled Digital Engagement and Retention Solution
Industry-leading behavioral science tool SPUR™ is validated to predict adherence and will be offered through the Clinical ink technology platform
Clinical ink Announces the Promotion of John Pappadakis to Chief Commercial Officer and Megan Petrylak to Chief Operating Officer
Clinical ink, a global life science technology company, announces the promotion of John Pappadakis from EVP, Global Business Development to Chief Commercial Officer and Megan Petrylak from EVP, Clinical Operations to Chief Operating Officer.
Clinical ink announces EDCXtra™ : An integrated web-based EDC, DDC and eCOA platform
Clinical ink announces EDCXtra: An integrated web-based EDC, DDC and eCOA platform.
Clinical ink announces EDCXtra™ : An integrated web-based EDC, DDC and eCOA platform Read More...
Clinical ink Appoints Dr. Nicholas Alp, MD PhD as Chief Medical Officer
Clinical ink announced the appointment of Dr. Nicholas Alp as Chief Medical Officer will lead the creation of innovative solutions and commercial strategies for clinical trial technology based on his experience as an interventional cardiologist and clinical trialist.
Clinical ink Appoints Dr. Nicholas Alp, MD PhD as Chief Medical Officer Read More...
Clinical ink announces GlucoseReady™
Clinical ink announces an integrated suite of eClinical tools for cardiometabolic clinical trials.
Clinical ink announces GlucoseReady™ Read More...
